Halozyme Therapeutics, Inc. (HALO) — closed signal from November 4, 2025
Partial Published before the outcome was known, scored automatically when the window closed on February 2, 2026.
Predicted vs. what happened
What happened
Reached 60% of the predicted growth at its peak, without hitting the target.
The thesis — published November 4, 2025
Halozyme looks set for near-term strength. More buyers than usual and an improving trend suggest buying small dips. Recent research kept a $90 target and sees a good chance the next quarter beats expectations. The Elektrofi deal adds more ways to deliver medicines. Royalties keep stacking up, giving clearer income. A 0-3 month climb from recent price areas is likely, though biotech stocks can swing sharply.
Primary drivers
- Royalties from ENHANZE add steady profit power over the next few quarters
- Analyst H.C. Wainwright kept a $90 target, signaling continued confidence
- Improving trend with lots more buying than usual in recent trading
- Elektrofi purchase widens drug-delivery tools HALO offers its partners
How it played out
HALO: rose but stayed below the target
Lyra published HALO at $68.24 on 2025-11-04 with an 18% expected gain and a $80.52 target. The thesis expected a 0-3 month climb. It pointed to ENHANZE royalties, an H.C. Wainwright $90 target, heavier buying, an improving trend, and the Elektrofi deal adding more drug-delivery tools.
Inside the window from 2025-11-04 to 2026-02-02, HALO peaked at $75.59 on 2026-01-07. The peak gain was 10.8%, but the stock never reached $80.52. It ended at $74.45. The thesis partially played out: direction was right, but the target was missed.
What happened during the window
On 2025-11-12, Investor's Business Daily reported that HALO's Relative Strength Rating rose to 82 from 69. On 2025-12-26, it reported that the rating later rose to 75 from 69 while the stock was still below a cited 79.50 buy point.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.